These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 33105763)

  • 21. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors.
    Chiriacò M; Tricò D; Solini A
    Curr Opin Pharmacol; 2022 Oct; 66():102272. PubMed ID: 35964531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
    Vallon V; Verma S
    Annu Rev Physiol; 2021 Feb; 83():503-528. PubMed ID: 33197224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Communication by SGLT2 Inhibition.
    Billing AM; Kim YC; Gullaksen S; Schrage B; Raabe J; Hutzfeldt A; Demir F; Kovalenko E; Lassé M; Dugourd A; Fallegger R; Klampe B; Jaegers J; Li Q; Kravtsova O; Crespo-Masip M; Palermo A; Fenton RA; Hoxha E; Blankenberg S; Kirchhof P; Huber TB; Laugesen E; Zeller T; Chrysopoulou M; Saez-Rodriguez J; Magnussen C; Eschenhagen T; Staruschenko A; Siuzdak G; Poulsen PL; Schwab C; Cuello F; Vallon V; Rinschen MM
    Circulation; 2024 Mar; 149(11):860-884. PubMed ID: 38152989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.
    Shibata R; Taguchi K; Kaida Y; Fukami K
    Clin Exp Nephrol; 2023 Jan; 27(1):44-53. PubMed ID: 36114995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes.
    Linden MA; Ross TT; Beebe DA; Gorgoglione MF; Hamilton KL; Miller BF; Braun B; Esler WP
    Metabolism; 2019 Aug; 97():68-80. PubMed ID: 31132381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.
    Lytvyn Y; Bjornstad P; Katz A; Singh SK; Godoy LC; Chung LT; Vinovskis CL; Pyle L; Roussel R; Perkins BA; Cherney D
    Diabetes Metab; 2020 Jun; 46(3):203-209. PubMed ID: 31816431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study.
    Boeckhaus J; Gross O
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
    Tejedor Jorge A
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.